Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
784 Views
Dr KK Aggarwal 15 October 2019
The US FDA has approved a new drug “lefamulin” as treatment for adults with community-acquired bacterial pneumonia. It will be available as oral and intravenous (IV) formulations both.
The drug is a semisynthetic pleuromutilin that inhibits prokaryotic ribosomal protein synthesis through a unique mechanism that reduces its likelihood of developing resistance to bacteria or cross-resistance with the β-lactam, fluoroquinolone, glycopeptide, macrolide, and tetracycline antibiotic classes.
Side effects: Diarrhea, nausea, reactions at the injection site, elevated liver enzymes and vomiting
Contraindications
Warning
Women who could become pregnant should be advised to use effective contraception during lefamulin treatment and for two days after the final dose.
(Source: FDA, JAMA Oct. 1, 2019)
Dr KK Aggarwal
Padma Shri Awardee
President Confederation of Medical Associations in Asia and Oceania (CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of India
Past National President IMA
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}